clinical trial · NCT06653842
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 (Sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
Cutaneous Venous MalformationsQTORIN 3.9% rapamycin anhydrous gel
brief summary
A Phase 2, Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX022 (sirolimus) Topical Gel 3.9% in the Treatment of Cutaneous Venous Malformations
started
Dec 20, 2024
primary completion
Nov 21, 2025
completion
Mar 1, 2026
last updated
Mar 27, 2026
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol